SPRO Relative Valuation
SPRO's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. If the market price exceeds this fair value range, SPRO is overvalued; if below, it's undervalued.
Historical Valuation
Spero Therapeutics Inc (SPRO) is now in the Fair zone, suggesting that its current forward PS ratio of 0.00 is considered Fairly compared with the five-year average of -2.58. The fair price of Spero Therapeutics Inc (SPRO) is between NaN to NaN according to relative valuation methord.
Relative Value
Fair Zone
NaN-NaN
Current Price：2.27
Fair
-3.21
PE
1Y
3Y
5Y
Trailing
Forward
0.00
EV/EBITDA
Spero Therapeutics Inc. (SPRO) has a current EV/EBITDA of 0.00. The 5-year average EV/EBITDA is -1.21. The thresholds are as follows: Strongly Undervalued below -5.19, Undervalued between -5.19 and -3.20, Fairly Valued between 0.78 and -3.20, Overvalued between 0.78 and 2.77, and Strongly Overvalued above 2.77. The current Forward EV/EBITDA of 0.00 falls within the Historic Trend Line -Fairly Valued range.
-2.24
EV/EBIT
Spero Therapeutics Inc. (SPRO) has a current EV/EBIT of -2.24. The 5-year average EV/EBIT is -1.20. The thresholds are as follows: Strongly Undervalued below -4.62, Undervalued between -4.62 and -2.91, Fairly Valued between 0.51 and -2.91, Overvalued between 0.51 and 2.22, and Strongly Overvalued above 2.22. The current Forward EV/EBIT of -2.24 falls within the Historic Trend Line -Fairly Valued range.
18.42
PS
Spero Therapeutics Inc. (SPRO) has a current PS of 18.42. The 5-year average PS is 12.21. The thresholds are as follows: Strongly Undervalued below -17.69, Undervalued between -17.69 and -2.74, Fairly Valued between 27.15 and -2.74, Overvalued between 27.15 and 42.10, and Strongly Overvalued above 42.10. The current Forward PS of 18.42 falls within the Historic Trend Line -Fairly Valued range.
0.00
P/OCF
Spero Therapeutics Inc. (SPRO) has a current P/OCF of 0.00. The 5-year average P/OCF is -3.43. The thresholds are as follows: Strongly Undervalued below -9.49, Undervalued between -9.49 and -6.46, Fairly Valued between -0.41 and -6.46, Overvalued between -0.41 and 2.62, and Strongly Overvalued above 2.62. The current Forward P/OCF of 0.00 falls within the Overvalued range.
0.00
P/FCF
Spero Therapeutics Inc. (SPRO) has a current P/FCF of 0.00. The 5-year average P/FCF is -2.69. The thresholds are as follows: Strongly Undervalued below -8.15, Undervalued between -8.15 and -5.42, Fairly Valued between 0.05 and -5.42, Overvalued between 0.05 and 2.78, and Strongly Overvalued above 2.78. The current Forward P/FCF of 0.00 falls within the Historic Trend Line -Fairly Valued range.
Spero Therapeutics Inc (SPRO) has a current Price-to-Book (P/B) ratio of 4.85. Compared to its 3-year average P/B ratio of 1.61 , the current P/B ratio is approximately 201.87% higher. Relative to its 5-year average P/B ratio of 2.29, the current P/B ratio is about 111.41% higher. Spero Therapeutics Inc (SPRO) has a Forward Free Cash Flow (FCF) yield of approximately 0.00%. Compared to its 3-year average FCF yield of -16.94%, the current FCF yield is approximately -100.00% lower. Relative to its 5-year average FCF yield of -39.26% , the current FCF yield is about -100.00% lower.
4.85
P/B
Median3y
1.61
Median5y
2.29
-21.54
FCF Yield
Median3y
-16.94
Median5y
-39.26
Competitors Valuation Multiple
The average P/S ratio for SPRO's competitors is 0.00, providing a benchmark for relative valuation. Spero Therapeutics Inc Corp (SPRO) exhibits a P/S ratio of , which is NaN% above the industry average. Given its robust revenue growth of -59.60%, this premium appears unsustainable.
P/S
P/E
EV/EBITDA
EV/EBIT
P/S
Revenue Growth
Market Cap
Performance Decomposition
1Y
3Y
5Y
Market capitalization of SPRO increased by 121.36% over the past 1 year. The primary factor behind the change was an decrease in P/E Change from -1.05 to -2.88.
The secondary factor is the Margin Expansion, contributed 6.55%to the performance.
Overall, the performance of SPRO in the past 1 year is driven by P/E Change. Which is more unsustainable.
People Also Watch
FAQ
Is Spero Therapeutics Inc (SPRO) currently overvalued or undervalued?
What is Spero Therapeutics Inc (SPRO) fair value?
How does SPRO's valuation metrics compare to the industry average?
What is the current P/B ratio for Spero Therapeutics Inc (SPRO) as of Dec 05 2025?
What is the current FCF Yield for Spero Therapeutics Inc (SPRO) as of Dec 05 2025?
What is the current Forward P/E ratio for Spero Therapeutics Inc (SPRO) as of Dec 05 2025?